Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Processa hands cancer drug back to Opus over time, cost involved
The portfolio streamlining is meant to help Processa focus on another oncology asset, a modified precursor of approved chemotherapy 5-fluorouracil.
Darren Incorvaia
Jul 1, 2025 11:12am
Sanofi takes up option on Adagene biospecific, invests $25M
Jul 1, 2025 8:10am
Argenx's $1.5B pact to turn macrocyclic peptides to new targets
Jul 1, 2025 8:00am
BerGenBio, following lead drug's failure, merges with Oncoinvent
Jul 1, 2025 7:00am
Henlius pens $202M pact for HanchorBio's midstage CD47 blocker
Jul 1, 2025 3:50am
Pfizer expands XtalPi small-molecule discovery collab
Jun 30, 2025 10:00am
